Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China

Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China

Objective: This prospective observational study investigated the efficacy of tumor necrosis factor inhibitors (TNFis) on disease activity, physical functionality, and mobility in patients with ankylosing spondylitis (AS) in a real-world setting.Methods: The Chinese Ankylosing Spondylitis Prospective...

Full description

Bibliographic Details
Main Authors:	Xiaojian Ji, Yiwen Wang, Zhengyuan Hu, Yingpei Ma, Siliang Man, Kunpeng Li, Yanyan Wang, Jian Zhu, Jianglin Zhang, Feng Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-12-01
Series:	Frontiers in Pharmacology
Subjects:	tumor necrosis factor ankylosing spondylitis disease activity real-world study adalimumab biosimilar etanercept
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.01476/full

Similar Items

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
by: James Cheng-Chung Wei, et al.
Published: (2020-10-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01)

A case of chronic lymphocytic leukemia still taking etanercept for ankylosing spondylitis
by: ŞERİFE MEHLİKA KUŞKONMAZ, et al.
Published: (2016-01-01)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
by: Dubravka Bosnić, et al.
Published: (2016-12-01)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
by: Zena Chen, et al.
Published: (2021-09-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

Criptosporidiose em paciente com espondilite anquilosante usando adalimumabe Cryptosporidiosis in a patient with ankylosing spondylitis treated with adalimumab
by: Fernando Augusto Chiuchetta
Published: (2010-06-01)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
by: Evripidis Kaltsonoudis, et al.
Published: (2019-07-01)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
by: Yudai Suzuki, et al.
Published: (2021-08-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)

Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison
by: Yehua Wang, et al.
Published: (2016-09-01)

THE FIRST EXPERIENCE IN USING ADALIMUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL AND MRICOMPARISONS OF THE RESULTS OF THERAPY
by: A G Bochkova, et al.
Published: (2010-02-01)

THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01)

Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
by: Bahar Say, et al.
Published: (2019-09-01)

Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
by: V. Shobha, et al.
Published: (2019-07-01)

Management of ankylosing spondylitis; present concepts and guidelines
by: Ramaswamy Subramanian, et al.
Published: (2020-01-01)

Efficiency of drug therapy for coxitis in patients with ankylosing spondylitis according to the data of a 12-month prospective follow-up
by: A. V. Petrov, et al.
Published: (2019-01-01)

IMPACT OF THE THERAPY WITH TUMOR NECROSIS FACTOR α INHIBITORS ON THE FREQUENCY OF UVEITIS EXACERBATIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Alla A Godzenko, et al.
Published: (2014-03-01)

Spondylodiscitis in ankylosing spondylitis: Andersson lesion
by: B N Shiva Prasad, et al.
Published: (2020-01-01)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
by: Liudan Tu, et al.
Published: (2020-11-01)

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
by: Jinmei Su, et al.
Published: (2020-12-01)

Current treatment approaches in patients with ankylosing spondylitis
by: Bilal Elbey
Published: (2015-03-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Ankylosing Spondylitis
by: Nazanin Ebrahimiadib, et al.
Published: (2021-07-01)

Prevalence of fibromyalgia in patients with ankylosing spondylitis
by: Aref Hosseinian Amiri, et al.
Published: (2014-01-01)

Raised inflammatory markers as predictors of response to anti-tumor necrosis factor drugs (etanercept and infliximab) in a sample of Iraqi patients with ankylosing spondylitis
by: Saif Abdulkareem Raoof Al-Shaibani, et al.
Published: (2021-01-01)

The abilities of golimumab in the therapy of ankylosing spondylitis
by: Sh. F. Erdes
Published: (2014-09-01)

OSTEOPOROSIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Elena Efimovna Gubar, et al.
Published: (2013-12-01)

The Association of Acromegaly and Ankylosing Spondylitis
by: Alpaslan Tuzcu, et al.
Published: (2004-01-01)

Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment
by: M. Benucci, et al.
Published: (2016-12-01)

Epidemiology of ankylosing spondylitis utilizing the Scotland and Ireland Registry for Ankylosing Spondylitis
by: Dean, Linda E.
Published: (2015)

An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus
by: Ursula Schulte-Wrede, et al.
Published: (2018-08-01)

Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data
by: A. V. Petrov, et al.
Published: (2021-01-01)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
by: Bruna O. Ascef, et al.
Published: (2021-07-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis
by: R. O. Dreval
Published: (2021-02-01)

Atherosclerosis in Egyptian patients with ankylosing spondylitis
by: Dahlia A Hussein, et al.
Published: (2014-01-01)